New program halts population weight gain in Colorado clinics

A novel weight management initiative called PATHWEIGH, developed by endocrinologist Leigh Perreault, has successfully stopped population-level weight gain in primary care settings across Colorado. Tested in a large-scale trial involving over 274,000 patients, the program increased access to obesity treatments and is now attracting interest from health systems nationwide. Published results show a 0.58 kg reduction in average weight gain over 18 months, marking a significant public health advancement.

Endocrinologist Leigh Perreault, a professor at the University of Colorado Anschutz School of Medicine who practices in Westminster, grew frustrated with standard weight management advice in primary care. Patients often left with generic recommendations to eat better and exercise more, despite ongoing issues like diabetes and hypertension. Perreault realized many medications treated symptoms rather than addressing obesity as the root cause. "None of these people want to be on these medications and I thought if I could just help them with their weight, many of these health concerns would probably go away," she said.

To tackle this, Perreault and colleagues created PATHWEIGH, a structured system funded by the National Institutes of Health. It rolled out across 56 UCHealth primary care clinics in Colorado, involving 274,182 patients in one of the largest randomized trials of its kind. The program features dedicated visits focused solely on weight care, triggered by patient requests at the front desk. This activates an electronic health record workflow, including a patient survey that streamlines clinician notes and emphasizes practical steps.

Results, published in Nature Medicine in 2025, revealed PATHWEIGH reduced average population weight gain by 0.58 kg over 18 months, reversing the typical upward trend. It boosted the likelihood of receiving weight-related care by 23%, with one in four eligible patients accessing services like lifestyle counseling. Prescriptions for anti-obesity medications doubled during the trial. "With PATHWEIGH, we showed that we absolutely eliminated population weight gain across all of our primary care, which has never been done previously," Perreault noted.

The approach customizes treatments, reduces awkward weight discussions, and builds a clear pathway for care, likened by Perreault to a "highway" for various weight loss options. While individual changes may seem modest, they hold substantial public health value against annual average gains of about 0.5 kg. The Obesity Association now recommends PATHWEIGH in its standards, and five health systems in seven states are exploring adoption. Perreault calls it a "home-grown" blueprint for advancing obesity care.

相关文章

Split-image illustration contrasting swift private clinic access to Mounjaro for the wealthy versus long NHS queues for obesity patients in the UK.
AI 生成的图像

UK researchers warn NHS rollout of Mounjaro could widen inequalities in obesity care

由 AI 报道 AI 生成的图像 事实核查

UK specialists say strict early access rules for the weight-loss drug tirzepatide (Mounjaro) risk creating a “two-tier” obesity treatment system, with people who can pay privately getting faster access than those relying on the National Health Service.

Obesity has surged in South Africa, affecting nearly 11 million adults and costing R33 billion in 2020, equivalent to 16% of government health spending. Despite effective treatments like bariatric surgery and GLP-1 drugs such as Ozempic and Wegovy, medical schemes limit coverage, exacerbating the financial strain on patients and funders. New guidelines aim to reframe obesity as a chronic disease to improve access.

由 AI 报道

A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.

Brazil's Anvisa approved on Monday, February 2, 2026, the expansion of therapeutic indications for semaglutide, the active ingredient in Wegovy and Ozempic. Wegovy can now be used to reduce the risk of heart attacks and strokes in adults with cardiovascular disease and overweight, while Ozempic is indicated for type 2 diabetes associated with chronic kidney disease. The agency is also reviewing a request for an oral version of Wegovy.

由 AI 报道 事实核查

Scientists are probing brain circuits affected by GLP-1 medicines such as Ozempic, Wegovy, Mounjaro, and Zepbound to preserve weight-loss benefits while curbing nausea. The findings, presented at Neuroscience 2025, outline strategies that could refine treatments for obesity and type 2 diabetes.

Market data shows that users of GLP-1 weight loss drugs in the US are driving higher sales of premium chocolate, contrary to earlier expectations of declining demand. Households using these medications account for a larger share of chocolate purchases despite reduced overall appetite. This trend highlights a shift toward quality over quantity in indulgences.

由 AI 报道 事实核查

Households that start GLP-1 appetite-suppressing medications such as Ozempic and Wegovy reduce food spending within months, including at grocery stores and limited-service restaurants, according to new research from Cornell University based on linked survey responses and transaction data.

 

 

 

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝